Forster Discovery is an independent consultancy supporting biotech teams, founders, investors and R&D organisations across medicinal chemistry, computational drug design, synthetic strategy, targeted protein degradation and outsourced R&D.
Better compound choices. Practical synthetic routes. Clearer program decisions.
Engagements are built around concrete technical decisions — from compound prioritisation to route strategy, outsourced-program steering and independent diligence.
Data-package review, compound prioritisation, design recommendations and DMPK-informed decision support.
Recurring chemistry support for virtual and small biotech teams without an experienced internal chemistry lead.
Mechanistic and chemistry-oriented program assessment for targeted protein degradation and molecular-glue projects.
Synthetic-route design, feasibility, scale-up risk assessment, CRO/CDMO briefing and troubleshooting.
Technical briefing, communication, prioritisation and problem-solving across outsourced chemistry programs.
Independent scientific review for founders, investors, boards and prospective partners.
Independent scientific input that helps drug-discovery teams make better technical decisions and act on them.
Compound design considered together with synthetic feasibility, route robustness and practical execution.
SAR, DMPK interpretation, CADD/RDKit/Python and TPD / molecular-glue experience brought into the same decision.
Experience on both sides of outsourced R&D supports sharper briefs, better prioritisation and more productive external partnerships.
A technically grounded view for teams, investors and boards that is separate from the vendor or internal project narrative.
PhD chemist with experience across biotech, CROs and academic research, including medicinal chemistry, TPD / molecular glues, synthetic route development, CRO leadership, structure-based design and IP.
Medicinal-chemistry campaigns from compound design and SAR through ADME/DMPK and in vivo PK selection, supported by structure-based and advanced computational modelling.
Multistep synthesis, route design, troubleshooting and process-oriented chemistry across internal and contract settings.
Scientific oversight of global CRO chemistry teams and technical steering of outsourced discovery work.
Co-inventor on six published patent families, with peer-reviewed publications and invited scientific presentations.
Scope and fees are agreed according to project complexity, required depth and duration.
A bounded review with analysis, prioritisation and a concrete decision-oriented output.
For medicinal chemistry, route development, program assessment or CRO/CDMO challenges with a defined scope.
Recurring program reviews, design input, prioritisation and outsourced-R&D oversight without a permanent hire.
Scientific review for investors, venture teams, boards, founders, licensing discussions or prospective partners.
Support can sit alongside internal biology, external chemistry, investment diligence or portfolio decision-making.
For programs that need experienced chemistry input without immediately building a larger internal chemistry function.
For teams deciding what to make next, how to interpret SAR / DMPK, or how to translate biology into a practical chemistry plan.
Independent assessment of chemistry quality, synthetic feasibility, program risk and the credibility of the proposed development path.
Technical input around partnering, licensing, program review, external-R&D strategy or major portfolio decisions.
A first conversation can clarify the scientific question, the right scope and whether a focused review, project mandate, fractional engagement or diligence assignment is the best fit.